Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Alpha-1-Antitrypsin Enhances Fat Graft Survival in a Murine Model.

Halpern D., Farber I., Anav Y., Tsitrina A., Lewis EC., Silberstein E.

Animal Study with a reported sample of 8 on Chronic Wound, published in Adv Wound Care (New Rochelle) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Wound Care (New Rochelle) (2026)
Country
United States
Reported sample size
8
Source database
PubMed
PMID
40105893
DOI
10.1089/wound.2024.0176
Citations
1

Abstract (original English)

Objective Fat grafting is widely applied for various purposes, including volume restoration, improving tissue quality, and promoting wound healing, but it has poor long-term graft survival predictability. Alpha-1-antitrypsin (AAT) administration is hypothesized to improve fat graft outcomes by expediting inflammatory resolution and graft vascularity and reducing necrosis. Approach Mice heterozygote to human AAT was grafted fat under the scalp alongside 400 µg/graft AAT or albumin (ALB) on days 0 and 3. Graft volume was determined by micro-magnetic resonance imaging, and explants were assessed for viability, histology, immunohistochemistry, and expression of selected genes. AAT expression was examined in hypoxia-exposed adipose-derived stem cells (ADSCs). Results After 90 days, AAT-treated grafts maintained higher volumes (70.06% vs. 34.54%, n = 8, p = 0.02) and displayed improved tissue quality. On day 10 after grafting, grafts exhibited more blood vessels (mean 1.94/mm 2 vs. 0.33/mm 2 ) and 6.25-fold more adiponectin transcript levels ( n = 12, p = 0.02). Although day-3 interleukin (IL)-1β expression was 5-fold greater in AAT-treated grafts ( n = 6, p = 0.4), day-10 IL-1β expression was 2-fold lower compared to ALB-treated grafts ( n = 22, p = 0.01). In the Methoxynitrosulfophenyl-tetrazolium carboxanilide (XTT) assay, day-3 AAT-treated grafts were 1.56-fold more metabolically

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Animalsalpha 1-AntitrypsinMiceGraft SurvivalAdipose TissueWound HealingMice, Inbred C57BLDisease Models, AnimalMaleModels, Animal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research